Rossari Biotech logo

Rossari Biotech financials: balance sheet, profit and loss, cash flow

NSE: ROSSARIBSE: 543213Chemicals & PetrochemicalsSmall Cap

Rossari Biotech Limited · Face value ₹2 · Listed Jul 2020 · Issue price ₹425
Last close ₹408.40up ₹0.05 (0.01%)BSE ₹407.45

Share price at the NSE close on 28 Oct 2026. Previous close ₹408.35.

28 Oct: open ₹408.25, high ₹414.25, low ₹403.35

52-week range of traded prices to 28 Oct 2026
₹375.00Low, 30 Mar 2026₹663.00High, 28 Oct 2025
Market cap
₹2,262 Cr1,009th largest listed
P/E
14.81
P/B
1.61
Dividend yield
0.12%
ROE
11.5%
ROCE
12.1%
Debt to equity
0.26
Volume, NSE
43,24648.6% delivered

Rossari Biotech's financial statements for the 6 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

6 years at a glance

₹ crore, years to March.Rossari Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
709800Mar 211,483988.4Mar 221,65610774Mar 231,831131106Mar 242,080136188Mar 252,396149408Mar 26
Peak revenue ₹2,396 Cr, year to Mar 2026; lowest ₹709 Cr, year to Mar 2021

Operating and net margin, per cent

  • Operating margin
  • Net margin
17.3%6.2%17.3%12.4%13.5%13.6%12.7%11.9%11.3%6.6%6.5%7.1%6.6%6.2%Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue2,396
  2. Materials and goods−1,669
  3. Employee costs−155
  4. Other expenses−287
  5. Operating profit286
  6. Depreciation−79
  7. Other income+22
  8. One-off items0.0
  9. Finance costs−29
  10. Profit before tax201
  11. Tax−53
  12. Joint ventures+1.9
  13. Net profit149

What the company owns

  • Plant, investments and other assets₹1,200 Cr
  • Receivables₹557 Cr
  • Inventory₹405 Cr
  • Cash and bank₹92 Cr
  • Current investments₹35 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,333 Cr
  • Borrowings₹408 Cr
  • Owed to suppliers₹323 Cr
  • Other liabilities₹224 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Rossari Biotech quarterly results

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 25 AprMar 2026Sep 2026Twelve monthsFiled 17 Oct
Revenue from operations7091,4831,6561,8312,0802,3962,661
5861,3001,4331,5811,8152,1102,348
Materials and goods bought4621,1051,1711,2941,4331,6691,865
Employee costs426899103132155167
Other expenses82127163184250287316
Operating profit before depreciation123183223250265286314
Operating margin17.3%12.4%13.5%13.6%12.7%11.9%11.8%
Materials, % of revenue65.2%74.5%70.7%70.7%68.9%69.6%70.1%
Employee costs, % of revenue5.9%4.6%6.0%5.6%6.4%6.5%6.3%
Other expenses, % of revenue11.6%8.5%9.8%10.1%12.0%12.0%11.9%
Depreciation and amortisation23486360677999
Operating profit after depreciation100135160189198207215
Other income9125742223
Finance costs3132219182936
One-off items0000000
Profit before tax106135143177184201202
27393747495351
Share of profit of joint ventures and associates0210122
8098107131136149153
Other comprehensive income0000−101
Total comprehensive income8098108131135149154
Net margin11.3%6.6%6.5%7.1%6.6%6.2%5.7%
Net margin without joint ventures and associates11.2%6.5%6.4%7.1%6.5%6.1%–

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 25 AprMar 2026Sep 2026Half yearFiled 17 Oct
4098059151,0481,1851,3331,408
Share capital10111111111111
Reserves3987949041,0371,1741,3221,397
0874106188408362
150295347425537790803
2157106100174166149
5611,2571,3681,5721,8962,2892,359
2076476467278531,0451,059
3556097218441,0421,2361,301
Net debt−88−55−773873281221
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 25 AprMar 2026Sep 2026Half year
48291524313765131
797920097197134157
−48−113−28−157−70−153−13
Receivables−40−43−28−113−85−135−16
Inventories−32−481−94−73−49−39
Payables24−22049853139
Other working capital00−10313
Tax paid−31−50−48−54−59−69−25
Capital spending58383313115926557
Free cash flow−10−9120−88−21−20074
−37−299−181−103−184−219−50
−25292611665186−72
Dividends paid3333333
Shares bought back0000000
Shares issued4330244510
Net change in cash−142232−44193210
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Rossari Biotech dividend history

₹ per shareMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 25 AprMar 2026
Earnings per share₹15.56₹17.81₹19.46₹23.67₹24.66₹26.95
Diluted earnings per share₹15.47₹17.70₹19.38₹23.62₹24.63₹26.93
Dividend per share₹0.50₹0.50₹0.50₹0.50₹0.50₹0.50
Book value per share₹78.72₹146.25₹165.92₹189.65₹214.12₹240.74
Dividend payout3.2%2.8%2.6%2.1%2.0%1.9%
Shareholder yield−0.7%−6.0%0.0%0.0%−0.1%0.1%
Market cap at the year end (₹ crore)5,3785,0193,2883,7393,3472,097

Ratios

Consolidated, years to March.Rossari Biotech PE ratio and valuation

RatioMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 25 AprMar 2026
Revenue growth–109.1%11.7%10.5%13.6%15.2%
Operating profit growth–49.1%21.6%12.0%6.1%7.9%
Net profit growth–22.0%9.8%21.8%4.4%9.4%
Earnings per share growth–14.5%9.3%21.6%4.2%9.3%
19.6%16.1%12.5%13.3%12.2%11.8%
–−3.5 pts−3.6 pts0.8 pts−1.1 pts−0.4 pts
From the net margin–−8.2 pts−0.3 pts1.3 pts−1.1 pts−0.6 pts
From asset turnover–3.3 pts−3.6 pts−0.2 pts−0.4 pts−0.5 pts
From borrowing–1.3 pts0.2 pts−0.2 pts0.4 pts0.8 pts
Return on capital employed24.5%16.6%16.2%16.4%14.4%11.9%
Cash conversion59.7%30.1%142.1%33.1%100.8%43.6%
Interest cover33.510.77.29.811.17.2
Debt to equity0.000.010.080.100.160.31
Receivable days747578858385
Inventory days756359809088
Payable days1046158627371
Cash conversion cycle, days467679103101103
Working capital days606458848496
Asset turnover1.261.631.261.251.201.15
Assets per rupee of net worth1.371.501.531.501.551.66
Sales per rupee of plant4.234.285.285.825.884.28
Capital spending to depreciation2.540.800.522.172.363.35
Plant being built, % of plant in use0.2%0.4%4.2%15.0%39.7%30.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
7.1%
Cash from operations against operating profit
22.8%
Measure5 years3 years
Revenue growth, yearly rate27.6%13.1%
Profit growth, yearly rate13.2%11.6%
Return on equity, average13.2%12.5%
Return on capital employed, average15.1%14.2%
Operating margin, average12.8%12.8%
Net margin, average6.6%6.6%
Asset turnover, average1.301.20
Cash conversion cycle, days, average92102
Interest cover, average9.29.4
Debt to equity, average0.130.19

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations42824665
Cash from investing−986−506−219
Cash from financing620267186
Capital spending626554265
Dividends paid1483
Shares bought back000
Shares issued for cash315101
Borrowings raised469404240
Borrowings repaid757020

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––5643
Altman Z-scorePublished threshold 1.8124.499.427.227.105.463.74
Beneish M-scorePublished threshold −1.78–0.02−2.72−2.04−2.48−2.31
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–40.4010.3512.9710.5314.51
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.810.670.890.59
Receivables growth less revenue growthOur threshold 0 percentage points–2.544.359.66−2.032.28
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−39.90−6.7639.3614.96−2.50
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–1.57−1.272.161.392.04
Assets under construction, years of additionsOur threshold 2 years of additions–0.010.440.771.320.61
Effective tax ratePublished threshold 17.16 per cent25.1728.6425.8026.4526.5026.57
Tax charged less tax paid, % of profitOur threshold 10 percentage points–−8.57−7.55−3.92−5.64−7.70
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 May 2026ICRA LimitedInterchangeable limits-Working capital demand loan[ICRA]A1+Review, Other20
7 May 2026ICRA LimitedNon-fund based-Others[ICRA]A1+Review, Other23.31
7 May 2026ICRA LimitedFund-based-Term loan[ICRA]AA-Review, OtherPositive60
7 May 2026ICRA LimitedUnallocated limits-Unallocated limits[ICRA]AA- /[ICRA]A1+Review, OtherPositive10
7 May 2026ICRA LimitedFund-based-Cash credit[ICRA]AA-Review, OtherPositive240
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.